LABETALOL HYDROCHLORIDE

Post-LOE

labetalol hydrochloride

Hikma

ANDAINJECTIONINJECTABLE

Approved

Sep 2021

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

LABETALOL HYDROCHLORIDE (labetalol hydrochloride) by Hikma is clinical pharmacology labetalol combines both selective, competitive alpha 1 -adrenergic blocking and nonselective, competitive beta-adrenergic blocking activity in a single substance. Approved for hypertension. First approved in 2021.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Labetalol combines both selective, competitive alpha 1 -adrenergic blocking and nonselective, competitive beta-adrenergic blocking activity in a single substance. In man, the ratios of alpha- to beta- blockade have been estimated to be approximately 1:3 and 1:7 following oral…

Worked on LABETALOL HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

LABETALOL HYDROCHLORIDE

Mechanism of Action

Indications (1)